These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
421 related articles for article (PubMed ID: 28294487)
1. Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study. Monforte V; Sintes H; López-Gallo C; Delgado M; Santos F; Zurbano F; Solé A; Gavaldá J; Borro JM; Redel-Montero J; Cifrian JM; Pastor A; Román A; Ussetti P Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28294487 [TBL] [Abstract][Full Text] [Related]
2. Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients. Mabilangan C; Preiksaitis J; Cervera C; Transpl Infect Dis; 2018 Oct; 20(5):e12964. PubMed ID: 29981174 [TBL] [Abstract][Full Text] [Related]
3. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients. Heldenbrand S; Li C; Cross RP; DePiero KA; Dick TB; Ferguson K; Kim M; Newkirk E; Park JM; Sudaria-Kerr J; Tichy EM; Ueda KR; Weng R; Wisniewski J; Gabardi S Transpl Infect Dis; 2016 Dec; 18(6):904-912. PubMed ID: 27639246 [TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus infection in heart transplantation: A single center experience. Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266 [TBL] [Abstract][Full Text] [Related]
5. Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients. Johansson I; Mårtensson G; Nyström U; Nasic S; Andersson R BMC Infect Dis; 2013 Dec; 13():582. PubMed ID: 24325216 [TBL] [Abstract][Full Text] [Related]
6. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation. Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085 [TBL] [Abstract][Full Text] [Related]
13. A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients. Monforte V; Lopez C; Santos F; Zurbano F; de la Torre M; Sole A; Gavalda J; Ussetti P; Lama R; Cifrian J; Borro JM; Pastor A; Len O; Bravo C; Roman A Am J Transplant; 2009 May; 9(5):1134-41. PubMed ID: 19344437 [TBL] [Abstract][Full Text] [Related]
14. Extending cytomegalovirus prophylaxis in high-risk (D+/R-) lung transplant recipients from 6 to 9 months reduces cytomegalovirus disease: A retrospective study. Herrera S; Khan B; Singer LG; Binnie M; Chaparro C; Chow CW; Martinu T; Tomlinson G; Keshavjee S; Husain S; Tikkanen JM Transpl Infect Dis; 2020 Aug; 22(4):e13277. PubMed ID: 32170813 [TBL] [Abstract][Full Text] [Related]